About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Our Science Discuva Platform Scientific Literature & Publications Investors Investor Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Pipeline Our promising pipeline of new mechanism antibiotics target a range of serious infectious diseases Home ∕ Our Pipeline ∕ Pipeline Our Pipeline Discuva Platform Discovery Preclinical Phase 1 Phase 2 Phase 3 C. difficile infection (ridinilazole) Discovery Preclinical Phase 1 Phase 2 Phase 3 Carbapenem-resistant Enterobacteriaceae (CRE) Infections (SMT-738)
Pipeline Our promising pipeline of new mechanism antibiotics target a range of serious infectious diseases
Home ∕ Our Pipeline ∕ Pipeline Our Pipeline Discuva Platform Discovery Preclinical Phase 1 Phase 2 Phase 3 C. difficile infection (ridinilazole) Discovery Preclinical Phase 1 Phase 2 Phase 3 Carbapenem-resistant Enterobacteriaceae (CRE) Infections (SMT-738)
